Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?
A Biotech Roundtable, Part 2
In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry.
You may also be interested in...
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.